A Randomised, Double-Blind, Active Placebo-Controlled, Parallel Groups, Dose-Response Study of Scopolamine Hydrobromide (4–6 Μg/Kg) in Patients With Major Depressive Disorder

Trials - United Kingdom
doi 10.1186/s13063-020-4089-6

Related search